In today's healthcare envirionment the key component is to have positive reimbursement.
We can work with you to assure that your development team includes into their phase III programs endpoints that can help justify cost effectiveness of a new therapy. We can help at the conclusion of your phase III programs to provide a cost effectiveness analysis as well as suggest study design for cost off-set modeling to help your teams establish value pricing. We can also assist in developing pre-launch payer advisory boards as well as dossier development.